Macrocyclic Tetrapeptides Selective KOR Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for addiction, particularly those targeting opioid receptors, face challenges in selectively targeting these receptors, crossing the blood-brain barrier, and providing long-lasting antagonism without significant side effects.
Innovation Solution
Development of novel macrocyclic tetrapeptides that potently and selectively antagonize the kappa opioid receptor (KOR) in vivo, offering oral availability and the ability to penetrate the central nervous system, thereby reducing or preventing opioid receptor activation and nociception.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional opioid therapies are used to target opioid receptors, then analgesic effects are achieved, but side effects increase and selectivity decreases
Solution Approach 1:
The invention segments the broad opioid receptor targeting into specific receptor subtypes (KOR, DOR, MOR) by designing peptides with selective binding profiles. The macrocyclic tetrapeptide structure enables preferential binding to KOR while minimizing activation of other opioid receptors, thereby achieving selectivity without proportional side effects
Solution Approach 2:
The patent applies local quality by modifying specific regions of the peptide structure (amino acid sequence, macrocyclization position, side chain composition) to optimize binding affinity for KOR while reducing off-target effects. The specific local structural features confer selective pharmacological properties
2Duration of action of moving object
If opioid antagonists are administered to block opioid receptors, then drug-seeking behavior is reduced, but duration of action is insufficient
Solution Approach 1:
The macrocyclic tetrapeptide structure provides continuous and sustained KOR antagonism through its stable conformation and high binding affinity. The cyclic structure resists proteolytic degradation and maintains pharmacological activity over extended periods, ensuring consistent duration of action
Solution Approach 2:
The invention uses a composite peptide structure combining specific amino acid residues in a macrocyclic arrangement, creating a molecule with enhanced stability and prolonged duration of action compared to linear peptides or small-molecule antagonists
3Reliability
If peptide-based opioid modulators are used, then selectivity is improved, but oral availability and CNS penetration are reduced
Solution Approach 1:
The patent changes critical parameters of the peptide including molecular size, flexibility (through macrocyclization), and amino acid composition to optimize oral bioavailability and CNS penetration while preserving selective KOR targeting. These parameter modifications enable the peptide to cross biological barriers
4Object-generated harmful factors
If macrocyclic tetrapeptides are designed for selective KOR antagonism, then side effects are reduced, but development complexity increases
Solution Approach 1:
The complex structure is segmented into four specific amino acid residues arranged in a macrocyclic pattern, where each residue contributes specific functional properties for KOR binding. This modular segmentation allows rational design while achieving the desired selectivity and reduced side effects
Data Source
AI summary
The disclosure relates to macrocyclic peptides and pharmaceutical compositions thereof. The disclosure further relates to pharmaceutical compositions for modulating opioid receptor activity. The macrocyclic tetrapeptides provided herein are useful in treating diseases or disorders relating to the activity of one or more opioid receptors, such as neurological disorders.